Use of metformin in diseases of aging

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Metformin is the most commonly prescribed medication for type 2 diabetes (T2DM) in the world. It has primacy in the treatment of this disease because of its safety record and also because of evidence for reduction in the risk of cardiovascular events. Evidence has accumulated indicating that metformin is safe in people with stage 3 chronic kidney disease (CKD-3). It is estimated that roughly one-quarter of people with CKD-3 and T2DM in the United States (well over 1 million) are ineligible for metformin treatment because of elevated serum creatinine levels. This could be overcome if a scheme, perhaps based on pharmacokinetic studies, could be developed to prescribe reduced doses of metformin in these individuals. There is also substantial evidence from epidemiologic studies to indicate that metformin may not only be safe, but may actually benefit people with heart failure (HF). Prospective, randomized trials of the use of metformin in HF are needed to investigate this possibility.

Original languageEnglish (US)
Article number490
JournalCurrent diabetes reports
Issue number6
StatePublished - Jun 2014


  • Aging
  • Chronic kidney disease
  • Diseases
  • Heart failure
  • Lactic acidosis
  • Metformin
  • Pharmacotherapy
  • Type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Use of metformin in diseases of aging'. Together they form a unique fingerprint.

Cite this